Belgian real-world date on the use of teclistamab in RRMM

During the 2025 IMS meeting, Prof Dr Marie-Christiane Vekemans, senior haematologist at the Cliniques Universitaires Saint-Luc in Brussels, shared the real-world experience with teclistamab in the treatment of relapsed/refractory multiple myeloma (RRMM) patients across three centres in Belgium

For this poster, outcomes were analysed for 53 patients with a median age of 63 years, most of whom presented with extra-medullary disease or high-risk cytogenetics. Notably, one-fifth had poor performance status (ECOG 3–4), underscoring the challenging baseline characteristics. 

At a median follow-up of 10 months, the overall response rate to teclistamab was 85%, with more than 80% achieving at least a very good partial response. The median time to best response was approximately 35 days, with median progression-free survival exceeding two years. 

Safety findings were consistent with what could be expected: cytokine release syndrome (CRS) and ICANS were observed but remained manageable with standard interventions, with only one case of grade 3 ICANS. Infectious complications were rare, likely due to the prophylactic use of immunoglobulins. 

Overall, these results align well with real-world data from other countries and with outcomes described in pivotal trials, supporting both efficacy and tolerability of teclistamab in this high-risk RRMM population.